Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Subcutaneous Doses of Cendakimab in Chinese Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cendakimab (Primary)
Indications Atopic dermatitis; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

31 Jul 2023 Status changed from active, no longer recruiting to completed.
03 May 2023 Planned End Date changed from 20 Apr 2023 to 12 Jun 2023.
03 May 2023 Planned primary completion date changed from 20 Apr 2023 to 12 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com